整理 | GLP1减重宝典内容团队诺和诺德近日宣布,其实验性减重药物 Amycretin 在早期临床试验中显示出显著疗效,超重和肥胖成人的体重最高减轻达 24%。这一结果为计划于明年启动的大型三期临床试验奠定了基础。公司表示,Amycretin 以每周注射或每日口服的形式给药,其不良反应主要集中在胃肠道,发生率与其他近期推出的减重药物相似。这项完整的试验结果已在芝加哥举行的美国糖尿病协会年会上公布...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.